Home >
Investors >
Events & Presentations
Investor FAQs
Analysts Coverage
Stock Information
Stock Chart & Quote

Historical Price Lookup

Investment Calculator

Preferred Shares

Acquisition of Allergan plc by AbbVie Inc.
Corporate Governance
Executive Officers and Directors

Committee Composition

Committee Charters

Code of Conduct

Governance Guidelines

Insider Transactions

Allergan Compliance Program

Memorandum of Association

Board Report

Shareholder Services
Information Requests

Investor Kit

E-mail Alerts

Dividends

Financial Information
SEC Filings

Annual Reports

Quarterly Results

Proxy Materials

Products >
Key Products
Our Products

Product Prescribing

Drug Safety
Quality
Patent Notices
Medical Information
Medical Information Request

R & D >
Open Science
R&D Areas of Focus
Our Pipeline
Clinical Trials
Post Marketing Commitments

Investigator Initiated Trials

Pre-Approval Access
About >
Executive Leadership
Global Footprint
Business Development

Global Locations
Commercial Operations

Countries

Contact
News >
CEO Blog
Press Releases
Media Contacts
Newsroom
Allergan Images

Allergan Logos

Executive Bios & Photos

Careers >
Career Opportunities
Working at Allergan
Our Employees
Ricardo Rouillon

Star Seyedkazemi

Albert Yao

Caitlin Sandahl

Jose Miguel Herrera

Shuyan Li

Christine Birchnall

Fellowship Program
Responsibility >
Social Contract
Social Responsibility
Community

Sustainability

Environmental

Employees

Partners

Public Policy

Allergan Foundation
California Supply Chain Disclosure
Alliance Support and IME Grants
Alliance Support

Independent Medical Education Grants

Health Care Provider Partnerships & Payments
Affordable Care Act

Patient Resources
Patient Assistance Programs

Patient Safety & Product Quality
Research and Development

Risks and Benefits

Quality

Animal Testing
>Go!
News > CEO Blog

FEATURED

BUILDING A CONSENSUS ON MEDICAL AESTHETIC TREATMENT FOR MINORS

As the father of two high school age girls, I am sensitive to the societal pressures they face – to look a certain way or meet a certain standard. And as the leader of Allergan, I appreciate how medical aesthetic technologies can...
​Read More
 
03
May
2016
The Power of Investment in Growth and Innovation
At Allergan, we have a strong commitment to investing in innovation to improve the lives of patients by addressing difficult to treat diseases. While investing in scientific innovation can be risky, a supportive legal and regulatory environment, as well as access to skilled workers and strong academic partners, creates an environment for success.
Read More
14
Apr
2016
Antibiotic Resistance – a Threat that Isn’t Going Away. Last week the White House called on Congress to shift leftover Federal funds from the...
Read More
29
Mar
2016
NIH Funding Fuels Innovation & Open Science. I felt very optimistic about the future of our Open Science model after reading that the U.S. Congress increased NIH funding of biomedical innovation by $2 billion. In a recent Wall Street Journal article NIH director Francis Collins shared...
Read More
Page 3 of 3
Share Post
Share on Facebook Share on Twitter Share on Google+ Share on LinkedIn View our RSS Feed
Follow Brent Saunders on Twitter
Follow Allergan on Twitter